骨质疏松症患者唑来膦酸用药评价与药学监护探索

Evaluation of Zoledronic Acid Use and Exploration of Pharmaceutical Monitoring in Patients with Osteoporosis

目的:探索骨质疏松症患者住院药学监护经验,分析临床唑来膦酸的合理应用情况。方法:选取2022年1~9月常州市第一人民医院收治的骨质疏松症患者为研究对象,评价唑来膦酸用药合理性,针对临床应用存在的主要问题,明确骨质疏松症患者唑来膦酸治疗住院药学监护要点,对2022年10~12月的患者进行药学监护,比较患者干预前后唑来膦酸用药情况。结果:未监测尿钙钠、骨代谢标志物,未合理补充维生素D及非甾体解热镇痛药的不合理应用为本院唑来膦酸临床应用存在的主要问题。实施药学监护后,骨质疏松症患者唑来膦酸用药合理率由实施前的5.00%(11/220)升至70.00%(42/60)。结论:对骨质疏松症患者唑来膦酸治疗住院实施药学监护,有助于提高唑来膦酸临床应用合理性。

Objective:To explore the inpatient pharmaceutical monitoring for osteoporosis patients and standardize the rational use of zoledronic acid in clinical practice.Methods:Osteoporosis patients admitted to Changzhou First People’s Hospital from January 2022 to September 2022 were selected as the research subjects,and the rationality of zoledronic acid medication was evaluated.The Plato method was used to identify the main problems in the clinical application of zoledronic acid,and the“Inpatient Pharmacological Monitoring Model for Zoledronic Acid Treatment of Osteoporosis Patients”was established.Pharmaceutical monitoring was conducted for patients from October to December 2022 according to this model,then the medication status of zoledronic acid in patients before and after the establishment of the model was compared.Results:Failure to monitor urinary calcium and sodium,unreasonable use of non steroidal antipyretic analgesics,failure to monitor bone metabolism markers,and inadequate supplementation of vitamin D were the main problems in the use of zoledronic acid in our hospital.After implementing pharmaceutical monitoring,the reasonable rate of zoledronic acid use in patients with osteoporosis increased from 5.00%(11/220)before implementation to 70.00%(42/60),with a statistically significant difference(P<0.05).Conclusion:Standardized management of osteoporosis patients in accordance with the“Zoledronic acid treatment inpatient pharmaceutical monitoring model”can help improve the rationality of zoledronic acid application.